Back to Results
First PageMeta Content
Clinical medicine / Cancer / Medicine / Cancer treatments / Organofluorides / Angiogenesis inhibitors / Eli Lilly and Company / Bevacizumab / FOLFIRI / FOLFOXIRI / Chemotherapy regimen / Cetuximab


References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC
Add to Reading List

Document Date: 2016-07-02 18:03:03


Open Document

File Size: 351,52 KB

Share Result on Facebook
UPDATE